Farmak searches for engaging startups in the innovative medical technology market in cooperation with Sector X.
“Why are we here? To find new business development points in P4 (predictive, preventive, personalized and participatory) medicine. Admittedly, the corporate sector may effectively operate a customized business model, but it is cumbersome enough to generate ideas and products that go beyond established stereotypes. Indeed, dozens of failures may often are behind the achievement of one success in the startup ecosystem, so the very recognition of the inevitability of mistakes and defeats gives unrestrained freedom of thought. Therefore, we are here to trace the breadth of the concept, the synergy between industry and creativity, which will allow us to find new and popular solutions for doctors, pharmacists, patients, to improve the quality of life and increase its duration,” Andriy Goy stated in his speech.
In cooperation with Sector X, Farmak has already reviewed about 20 proposals. 14 startups were presented at the opening, 3 of them were medical.
“This is just the beginning, there will be other startups. We take interest in the directions at the confluence of advanced near-patient testing, digital medicine, interactive patient involvement, which allow us to anticipate and prevent health problems, and if they are detected, to identify the causes and recommend solutions to the detected problems using biomedical and computing technologies,” Goy said.
Sector X is an accelerating platform that combines startup assistance in starting international business in close cooperation with Ukrainian and international corporations.
Scientists of the Institute of Medical Virology in Frankfurt am Main (Germany) conducted a study of the antiviral effect of the drug against SARS-COV-2 virus in a cell model. The drug was tested on human cells infected with SARS-COV-2 Enisamium showed a good effect. This was the reason for starting clinical trials of the drug […]
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...